Tetra Bio-Pharma, announced the appointment of Dr Guy Chamberland, an accomplished drug developer, as interim CEO. This appointment is effective immediately.
Dr Chamberland has been Chief Scientific Officer and Regulatory Affairs of Tetra since June 2016. He has more than 23 years' experience in the development of new drugs in the pharmaceutical industry in Canada and the US.
He worked for more than 10 years as an executive in various biopharmaceutical companies and was a member of the investment committee of a venture capital fund for 7 years.
Tetra's former CEO, Bernard Fortier, left the corporation 3 April, thereby terminating his role as CEO and member of the board of directors.
"We are thankful for Bernard's contributions to Tetra's activities," said André Rancourt, chairman of the board.
"Guy's role as interim CEO will be a tremendous asset at this stage of Tetra's growth. He will maintain his role and responsibility as Chief Scientific Officer while ensuring the growth and strategic operations of the corporation."
Chamberland will serve as interim CEO while the board of directors conducts a search for a new CEO.
